FIELD: medicine.
SUBSTANCE: invention can be used for carrying out the non-invasive diagnosis of the cirrhotic stage of chronic viral hepatitis C (CHC). The peripheral blood of a patient suffering from chronic viral hepatitis C is analysed to measure an absolute T-killer cell count with phenotype CD3+CD8+, and if the value is 295/l or less, the cirrhotic stage is diagnosed (F IV according to METAVIR).
EFFECT: higher sensitivity of the diagnostic technique for the cirrhotic stage of chronic viral hepatitis C, reducing the cost of the technique method, extending the population of patients in implementing the technique, if the patient has narrow rib spaces, suffers ascite and cholelithiasis.
1 dwg, 4 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| DIAGNOSTIC TECHNIQUE FOR HEPATIC CIRRHOSIS (STAGE F4) IN THE OUTCOME OF CHRONIC VIRAL HEPATITIS C | 2019 |
|
RU2724595C1 |
| METHOD OF HEPATIC FIBROSIS ASSESSMENT IN PATIENTS WITH CHRONIC VIRAL HEPATITIS TYPE C | 2009 |
|
RU2416794C1 |
| DIAGNOSTIC TECHNIQUE FOR STAGE OF CHRONIC HEPATITIS C IN RNA-HCV "+" PATIENTS | 2012 |
|
RU2486516C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF CHRONIC HEPATITIS B AND CHRONIC HEPATITIS C IN PATIENTS WITH SEVERE FIBROSIS AND CIRRHOSIS | 2024 |
|
RU2835987C1 |
| METHOD FOR PREDICTING THE ABSENCE OF REGRESS OF HEPATIC FIBROSIS IN THE PATIENTS WITH CHRONIC HEPATITIS C | 2019 |
|
RU2723387C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF CHRONIC HEPATITIS B, CHRONIC HEPATITIS C AND AUTOIMMUNE LIVER DISEASES IN PATIENTS WITH SEVERE FIBROSIS AND CIRRHOSIS | 2024 |
|
RU2834902C1 |
| METHOD FOR LABORATORY DIAGNOSIS OF STAGES OF HEPATIC FIBROSIS IN CHRONIC VIRAL HEPATITIS C | 2015 |
|
RU2583939C1 |
| METHOD FOR DETERMINING AVERAGE RATE OF FORMATION OF HEPATIC FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C | 2020 |
|
RU2739687C1 |
| METHOD OF DETERMINING THE AVERAGE RATE OF LIVER FIBROSIS FORMATION IN PATIENTS WITH CHRONIC HEPATITIS B+C | 2022 |
|
RU2801262C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF CHRONIC HEPATITIS C AND AUTOIMMUNE LIVER DISEASES IN PATIENTS WITH SEVERE FIBROSIS AND CIRRHOSIS | 2024 |
|
RU2834898C1 |
